In our study, we first determined that the expression of CYP19A1 in the plasma of drug-resistant breast cancer patients was significantly upregulated, indicated that the effect of CYP19A1 on drug sensitivity in breast cancer may be bidirectional. This evidence concerns the gene CYP19A1 and breast cancer.